Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Hepatology"
DOI: 10.1016/s0168-8278(17)31949-9
Abstract: Recent guidelines recommend that patients who failed DAAs treatment with nonstructural protein 5A inhibitors (NS5A) should be retreated 24 weeks with Sofosbuvir (SOF) combined with either a protease inhibitor for those with NS5A RAVs, or… read more here.
Keywords: active antivirals; antivirals genotype; genotype chronic; retreatment ... See more keywords